tmem39a Antibody

What is TMEM39A and what are its basic structural characteristics?

TMEM39A (Transmembrane Protein 39A) is a member of the TMEM39 family, characterized by 8 transmembrane helix segments within its sequence. In humans, the canonical protein has 488 amino acid residues with a molecular mass of approximately 55.7 kDa. It has been reported to have up to two different isoforms. TMEM39A is widely expressed across multiple tissue types and is primarily localized to the endoplasmic reticulum (ER) . Structurally, it's classified as a type 3-transmembrane protein according to Singer's classification . When selecting antibodies for TMEM39A detection, it's important to consider these structural characteristics to ensure proper epitope targeting.

What is the cellular localization and function of TMEM39A?

TMEM39A primarily localizes to the endoplasmic reticulum, though some studies have observed it in dot-like structures near the nucleus that may represent mitochondria or endosomes . Functionally, TMEM39A regulates autophagy by controlling the spatial distribution and levels of intracellular phosphatidylinositol 4-phosphate (PtdIns(4)P) pools . Recent research has expanded our understanding of its function, demonstrating that TMEM39A regulates lysosome dynamics through interactions with the dynein intermediate light chain DYNC1I2, maintaining proper lysosome distribution . When designing immunofluorescence experiments with TMEM39A antibodies, researchers should consider co-staining with organelle markers to accurately determine subcellular localization.

How is TMEM39A involved in disease pathology?

TMEM39A has been implicated in several autoimmune diseases. Genome-wide association studies have identified TMEM39A as a susceptibility locus for multiple sclerosis, systemic lupus erythematosus, and autoimmune thyroid disease . Additionally, TMEM39A is overexpressed in glioma cell lines and patient tissues, with higher expression correlating with poorer survival outcomes . The mechanistic link between TMEM39A dysfunction and disease likely involves its roles in lysosome dynamics, autophagy regulation, and mTOR signaling, all of which can affect immune function and cellular homeostasis .

What are the optimal applications for TMEM39A antibody detection?

Based on current research protocols, TMEM39A antibodies are most commonly used in Western blot analysis, immunohistochemistry (IHC), and immunocytochemistry/immunofluorescence (ICC/IF) . Recommended dilutions vary by application:

Researchers should optimize these dilutions for their specific experimental conditions and sample types . When analyzing TMEM39A expression in cancer tissues, IHC has proven particularly valuable for observing differential expression between tumor and surrounding normal tissues .

How should I design experiments to study TMEM39A's interaction with lysosomes?

When investigating TMEM39A's role in lysosome dynamics, a multi-method approach is recommended:

• Co-immunoprecipitation experiments to detect interactions between TMEM39A and dynein intermediate light chain DYNC1I2

• Live-cell imaging with fluorescently tagged TMEM39A and lysosomal markers to monitor lysosome distribution and mobility

• TMEM39A knockdown or knockout studies followed by assessment of:

  • Lysosome distribution (typically using LAMP1 or other lysosomal markers)

  • Lysosome tubularization

  • Lysosome mobility

In knockout models, researchers have observed redistribution of lysosomes from the perinuclear region to cell periphery and reduced lysosome mobility . These experiments should be complemented with rescue experiments to confirm specificity.

What controls should be included when using TMEM39A antibodies in Western blot analysis?

For rigorous Western blot analysis of TMEM39A, include the following controls:

• Positive controls: Glioblastoma cell lines with known TMEM39A expression (U87-MG, U251-MG, U343-MG, or U373-MG cells)

• Negative/low expression controls: Normal brain tissue lysates or HEK-293A cells (which show lower expression compared to glioblastoma cells)

• Loading controls: Standard housekeeping proteins like β-actin or GAPDH

• Antibody specificity controls: TMEM39A knockout or knockdown samples

• Size verification: The observed molecular weight should be approximately 48-56 kDa

When analyzing post-translational modifications like glycosylation, consider using deglycosylation enzymes to confirm bands representing modified TMEM39A.

How can I investigate the role of TMEM39A in autoimmune disease models?

To study TMEM39A in autoimmune disease contexts, consider these methodological approaches:

• Genetic association studies: Analyze specific TMEM39A SNPs (rs1132200, rs12492609, rs2282175, and rs7629750) in patient cohorts with autoimmune conditions

• Functional assays: Examine how TMEM39A variants affect:

  • Autophagy flux (using LC3B markers)

  • Lysosome distribution and function

  • mTOR signaling pathway activity

  • Cytokine production in immune cells

• Animal models: Generate TMEM39A knockout or knock-in models with disease-associated variants and assess autoimmune phenotypes

• Patient-derived cells: Compare TMEM39A expression and function in cells from patients with autoimmune diseases versus healthy controls

Research indicates that TMEM39A polymorphisms are particularly associated with early-onset autoimmune thyroid disease and Hashimoto's thyroiditis with hypothyroidism , suggesting age-stratified analyses may be valuable.

How does TMEM39A regulate autophagy, and what techniques can measure this function?

TMEM39A regulates autophagy through multiple mechanisms:

• Controls trafficking of the PtdIns(4)P phosphatase SAC1

• Maintains proper lysosome distribution via interaction with dynein

• Influences mTOR signaling, which regulates autophagy initiation

To methodically investigate these roles, researchers should:

• Measure autophagosome formation: Use mCherry::GFP::LC3B tandem fluorescence assays to distinguish autophagosome formation from autophagic flux

• Quantify LC3-II conversion: Western blot analysis of LC3-I to LC3-II conversion, with and without lysosomal inhibitors

• Assess mTOR activity: Measure phosphorylation of mTOR targets (p70S6K, 4E-BP1)

• Monitor Beclin-1 phosphorylation: Analyze Ser15 phosphorylation on Beclin-1, which is enhanced in TMEM39A knockout cells

• Track PtdIns(4)P distribution: Use specific probes to visualize PtdIns(4)P pools

Data from TMEM39A knockout cells show enhanced autophagosome formation even under non-starved conditions and further enhancement upon starvation, indicating its role as a negative regulator of autophagy initiation .

How do I address conflicting data regarding TMEM39A subcellular localization?

Different studies have reported TMEM39A localization to:

• The endoplasmic reticulum

• Dot-like structures near the nucleus, possibly mitochondria or endosomes

• Potential plasma membrane localization based on interactor proteins

To resolve these discrepancies:

• Use multiple antibodies: Validate findings with at least two different antibodies targeting distinct epitopes

• Employ subcellular fractionation: Biochemically separate cellular compartments to determine TMEM39A distribution

• Perform co-localization studies: Use confocal microscopy with established markers for:

  • ER (calnexin, PDI)

  • Mitochondria (MitoTracker, TOM20)

  • Endosomes (EEA1, Rab5)

  • Plasma membrane (Na+/K+ ATPase)

• Use epitope-tagged TMEM39A: Compare localization of tagged constructs with antibody staining of endogenous protein

• Consider cell type differences: Systematically compare localization across different cell types

The apparent discrepancies may reflect dynamic localization patterns, cell-type specificity, or technical limitations of different detection methods .

How should researchers investigate TMEM39A's role in glioma progression?

To thoroughly examine TMEM39A's involvement in glioma:

• Expression analysis: Compare TMEM39A levels across:

  • Glioma grades (I-IV)

  • Histological subtypes (GBM, oligodendroglioma, astrocytoma)

  • IDH-mutant versus wild-type tumors

  • Primary versus recurrent tumors

• Functional studies:

  • Generate TMEM39A knockdown/knockout in glioma cell lines

  • Assess effects on proliferation, migration, invasion, and apoptosis

  • Perform orthotopic xenograft studies to evaluate in vivo effects

• Mechanistic investigations:

  • Examine effects on autophagy and lysosomal function in glioma cells

  • Assess impact on mTOR signaling and downstream pathways

  • Investigate potential interactions with known glioma oncogenes/tumor suppressors

Research has demonstrated that TMEM39A is significantly upregulated in various gliomas compared to normal brain tissue, with high expression correlating with poorer survival (HR = 2.17, 95% CI 0.80–2.89) .

What experimental model systems are optimal for studying TMEM39A function?

Based on the literature, these model systems have proven effective for TMEM39A research:

• Cell lines:

  • Glioblastoma: U87-MG, U251-MG, U343-MG, U373-MG (high TMEM39A expression)

  • HEK293T cells (for heterologous expression studies)

  • Normal human astrocytes (as controls for brain tumor studies)

• Animal models:

  • C. elegans with tmem-39 knockout (for evolutionary conserved functions)

  • Mouse models with conditional TMEM39A knockout in specific tissues

• Patient-derived models:

  • Primary glioma cultures from patient samples

  • Patient-derived xenografts

  • Tissue microarrays for expression studies

The use of complementary models is recommended, as TMEM39A functions appear to be evolutionarily conserved from C. elegans to humans .

How can researchers investigate TMEM39A's interaction with dynein and its effect on lysosome positioning?

To study the TMEM39A-dynein interaction and its functional consequences:

• Protein-protein interaction studies:

  • Co-immunoprecipitation of TMEM39A with DYNC1I2

  • Proximity ligation assays to visualize interactions in situ

  • Domain mapping to identify specific interaction regions

• Live cell imaging:

  • Dual-color live imaging of lysosomes and TMEM39A

  • Fluorescence recovery after photobleaching (FRAP) to assess lysosome mobility

  • Single-particle tracking of lysosomes in control versus TMEM39A-deficient cells

• Dynein functional assays:

  • In vitro microtubule gliding assays with purified components

  • Analysis of dynein-dependent transport in the presence/absence of TMEM39A

Research has shown that TMEM39A interacts with dynein intermediate light chain to maintain proper lysosome distribution, and loss of TMEM39A leads to redistribution of lysosomes from the perinuclear region to cell periphery .

How do TMEM39A genetic variants impact protein function in autoimmune disease?

To characterize the functional impacts of disease-associated TMEM39A variants:

• Structure-function analysis:

  • Generate expression constructs with disease-associated SNPs

  • Assess effects on protein stability, localization, and post-translational modifications

  • Perform domain-specific mutagenesis to identify critical functional regions

• Cellular phenotyping:

  • Compare autophagy rates between cells expressing wild-type versus variant TMEM39A

  • Assess lysosome distribution and function

  • Measure inflammatory cytokine production

• Patient-derived cells:

  • Generate iPSCs from patients with disease-associated variants

  • Differentiate into relevant cell types (neurons for MS, B cells for SLE)

  • Compare cellular phenotypes with those from healthy controls

Research has identified specific SNPs (rs1132200, rs12492609, rs2282175, and rs7629750) associated with autoimmune thyroid disease, with the T allele of rs12492609 specifically linked to both AITD and Hashimoto's thyroiditis .

What are the methodological challenges in studying TMEM39A's role in mitophagy and how can they be addressed?

Investigating TMEM39A in mitophagy presents several challenges:

• Challenge: Distinguishing mitophagy from general autophagy
  Solution: Use mitophagy-specific reporters like mt-Keima or mito-QC; perform electron microscopy to visualize mitochondria within autophagosomes

• Challenge: Determining if TMEM39A directly affects mitophagy or acts indirectly
  Solution: Assess TMEM39A localization during mitophagy induction; examine interactions with known mitophagy regulators (PINK1, Parkin)

• Challenge: Separating effects on mitochondrial dynamics from mitophagy
  Solution: Measure mitochondrial fusion/fission rates independently; assess mitochondrial membrane potential and morphology

• Challenge: Tissue-specific variations in mitophagy regulation
  Solution: Compare TMEM39A function across multiple cell types; use tissue-specific knockout models

Current research suggests a potential role for TMEM39A in mitophagy based on its observed effects on lysosome dynamics and autophagy, but direct experimental evidence requires further investigation .